LP-856866 是一种口服有效的 ACSL5 抑制剂,对小鼠和人 ACSL5 的 IC50 分别为 8 和 4 nM,对小鼠和人 ACSL1 的 IC50 分别为 6 和 17 nM,可引发胃排空延迟、促进 GLP-1 释放、减少食物摄入、降低体重与体脂、保留瘦体重、改善葡萄糖稳态、增强胰岛素敏感性、减少肝脏脂肪堆积并降低血清甘油三酯与总胆固醇水平,可用于饮食诱导肥胖的研究。
LP-856866
产品编号: MS-F16919 纯度: 99.92% 分子式: C26H26F3NO5S 分子量: 521.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

LP-856866 是一种口服有效的 ACSL5 抑制剂,对小鼠和人 ACSL5 的 IC50 分别为 8 和 4 nM,对小鼠和人 ACSL1 的 IC50 分别为 6 和 17 nM,可引发胃排空延迟、促进 GLP-1 释放、减少食物摄入、降低体重与体脂、保留瘦体重、改善葡萄糖稳态、增强胰岛素敏感性、减少肝脏脂肪堆积并降低血清甘油三酯与总胆固醇水平,可用于饮食诱导肥胖的研究。

生物实验数据

生物活性 LP-856866 is an orally active ACSL5 inhibitor with IC50 values of 8 and 4 nM for mouse and human ACSL5, respectively, and 6 and 17 nM for mouse and human ACSL1, respectively; it delays gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic fat accumulation, and lowers serum triglyceride and total cholesterol levels, and can be used for the study of diet-induced obesity.
IC50 & Target

ACSL5

 

体内研究
(In Vivo)

LP-856866 (10-60 mg/kg/day; p.o.; 混饲; 共 28 天) 可在雄性饮食诱导肥胖小鼠中引发剂量依赖性的体重和体脂降低,同时保留瘦体重,并改善葡萄糖耐量和胰岛素敏感性。
LP-856866 (p.o.; 混饲) 可减少野生型小鼠的高脂饮食摄入量,但对 Acsl5 敲除小鼠无此作用,证实其可靶向抑制 ACSL5。
LP-856866 (75 mg/kg; p.o.; 混饲; 共 11 天) 会改变小鼠的饮食偏好,使其远离高脂饮食,减少总热量摄入,并阻止同时摄入低脂和高脂饮食的雄性小鼠体重增加。
LP-856866 (60 mg/kg/day; p.o.; 混饲; 共 17 天) 可降低饲喂高脂饮食的小家鼠的肝脏甘油三酯水平。
LP-856866 (60 mg/kg/day; p.o.; 混饲; 共 3 周) 可降低高脂饮食喂养小鼠的血清总胆固醇和甘油三酯水平。
LP-856866 (60 mg/kg; p.o.; 单次给药) 可提高雄性小鼠餐后活性 GLP-1 水平。

Animal Model: C57BL/6J-Tyrc−Brd X 129SvEvBrd hybrid (male; diet-induced obesity model, fed 45% high-fat diet from weaning for over 16 weeks)
Dosage: 10 mg/kg/day; 30 mg/kg/day; 60 mg/kg/day
Administration: p.o.; continuous dietary admixture; 28 days
Result: Induced significant, dose-dependent body weight loss and body fat loss with reduced lean body mass loss compared to vehicle-treated mice at 28 days.
Lowered glucose excursions at 30 minutes significantly in 30 mg/kg/day and 60 mg/kg/day groups compared to vehicle-treated mice during OGTT.
Reduced insulin excursions at 30 and 60 minutes significantly in all treated groups compared to vehicle-treated mice during OGTT.
Improved Homeostatic Model Assessment Insulin Sensitivity Index (HOMA ISI) and Composite ISI significantly in all treated groups compared to vehicle-treated mice.
Animal Model: C57BL/6J-Tyrc−Brd X 129SvEvBrd hybrid (male; chow-fed, acclimated to 10% low-fat diet for 2 weeks)
Dosage: 75 mg/kg/day
Administration: p.o.; continuous dietary admixture; 11 days
Result: Increased daily intake of 10% low-fat diet significantly and decreased daily intake of 60% high-fat diet significantly compared to vehicle-treated mice.
Lowered total caloric intake significantly on day 1 and throughout the study compared to vehicle-treated mice.
Reduced body weight change from day 0 significantly over the 11-day study compared to vehicle-treated mice.
Animal Model: C57BL/6J-Tyrc−Brd X 129SvEvBrd hybrid (male; fed Clinton 40% high-fat diet)
Dosage: 60 mg/kg/day
Administration: p.o.; continuous dietary admixture; 17 days
Result: Reduced hepatic triglyceride levels (measured as mg/liver and mg/g liver) significantly compared to vehicle-treated mice.
Animal Model: C57BL/6J-Tyrc−Brd X 129SvEvBrd hybrid (male; fed 45% high-fat diet)
Dosage: 60 mg/kg/day
Administration: p.o.; continuous dietary admixture; 3 weeks
Result: Reduced serum total cholesterol and serum triglyceride levels significantly compared to vehicle-treated mice.
Animal Model: C57BL/6J-Tyrc−Brd X 129SvEvBrd hybrid (male; fed 45% high-fat diet for at least 13 weeks)
Dosage: 60 mg/kg
Administration: p.o.; single pretreatment dose; 30 minutes before HFD meal
Result: Increased plasma active glucagon-like peptide-1 (aGLP-1) levels compared to vehicle treatment, with peak levels at 5-10 minutes after HFD meal.
Produced a synergistic increase in plasma aGLP-1 levels when combined with sitagliptin, with significantly higher levels at 5, 10, 15, 30, 60, 120, and 240 minutes after HFD meal compared to vehicle, sitagliptin alone, or LP-856866 alone.
性状 固体
颜色 White to light yellow

化学信息

分子量 521.55
分子式 C26H26F3NO5S

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (191.74 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.9174 mL9.5868 mL19.1736 mL47.9340 mL
5 mM0.3835 mL1.9174 mL3.8347 mL9.5868 mL
10 mM0.1917 mL0.9587 mL1.9174 mL4.7934 mL
15 mM0.1278 mL0.6391 mL1.2782 mL3.1956 mL
20 mM0.0959 mL0.4793 mL0.9587 mL2.3967 mL
25 mM0.0767 mL0.3835 mL0.7669 mL1.9174 mL
30 mM0.0639 mL0.3196 mL0.6391 mL1.5978 mL
40 mM0.0479 mL0.2397 mL0.4793 mL1.1984 mL
50 mM0.0383 mL0.1917 mL0.3835 mL0.9587 mL
60 mM0.0320 mL0.1598 mL0.3196 mL0.7989 mL
80 mM0.0240 mL0.1198 mL0.2397 mL0.5992 mL
100 mM0.0192 mL0.0959 mL0.1917 mL0.4793 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础